Moderna jumps ahead of May 1 earnings as traders lean into pipeline catalysts
MRNA•Moderna shares rose as investors positioned ahead of the company’s Q1 2026 earnings report due May 1, 2026, with traders focusing on potential guidance and pipeline updates. The move also comes after recent visibility around upcoming oncology disclosures at the 2026 ASCO meeting, keeping sentiment supported into the event window.
1. What’s moving the stock today
Moderna (MRNA) is trading higher as the market leans into a near-term catalyst setup: the company is scheduled to report first-quarter 2026 results on Friday, May 1, 2026, which is pulling in event-driven buyers and short-term positioning. With the stock having been volatile around prior reports, incremental demand ahead of earnings can be enough to lift shares on an otherwise quiet news day. (trefis.com)
